CMS launches Medicare GLP-1 Bridge to inform future obesity drug coverage

The CMS has launched the Medicare GLP-1 Bridge, a temporary demonstration providing eligible Medicare beneficiaries with access to selected obesity medicines for $50 per month. The initiative is intended to improve affordability while generating utilization data to inform potential implementation of the delayed BALANCE Model.

The Baseline

• The Medicare GLP-1 Bridge launched on July 1, 2026, providing eligible beneficiaries with access to selected GLP-1 medicines for $50 per month through December 2027.
• The demonstration operates outside Medicare Part D and is intended to generate utilization and cost data following the postponement of the Medicare component of the BALANCE model.
• Evidence generated through the Bridge is expected to inform future Medicare coverage decisions and any potential implementation of BALANCE.

The Centers for Medicare & Medicaid Services (CMS) has announced the official launch Medicare GLP-1 Bridge, a temporary demonstration that provides eligible Medicare beneficiaries with access to selected GLP-1 medicines. The initiative will serve as an interim access pathway while the agency gathers evidence to inform potential implementation of its longer-term Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) Model.

Beginning July 1, 2026, the demonstration will run through December 31, 2027 and operates outside the Medicare Part D prescription drug benefit. Eligible beneficiaries can obtain qualifying medicines for $50 per month, regardless of income, with CMS managing prior authorization, claims processing, and pharmacy payments through a centralized processor rather than Medicare Part D plans.

The launch follows a series of US government efforts to improve access to GLP-1 medicines, particularly for Medicare beneficiaries with obesity or overweight. In November 2025, the Trump Administration announced most-favored-nation (MFN) pricing agreements with Eli Lilly and Novo Nordisk intended to lower US prices for obesity and diabetes medicines while supporting domestic pharmaceutical manufacturing. CMS then introduced the voluntary BALANCE Model in January 2026 to test broader access to GLP-1 medicines across Medicare and Medicaid. However, CMS later postponed the Medicare Part D component of BALANCE after feedback from Part D sponsors indicated that additional utilization data would be needed before plans could commit to the voluntary coverage model. The Medicare GLP-1 Bridge is intended to provide that evidence while maintaining patient access to treatment.

Unlike the proposed BALANCE Model, which would require participating Part D plans and manufacturers to negotiate pricing and coverage arrangements, the Medicare GLP-1 Bridge does not require plan participation. Part D sponsors do not bear financial risk for medicines provided through the demonstration, and eligible beneficiaries can access treatment regardless of whether their plan participates in BALANCE.

Initially, the demonstration includes Wegovy (semaglutide; Novo Nordisk), Zepbound (tirzepatide; Eli Lilly), and Foundayo (orforglipron; Eli Lilly). Eligible beneficiaries must be enrolled in Medicare Part D, have not previously received a GLP-1 medicine through their Part D plan, and must not have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or metabolic dysfunction-associated steatohepatitis (MASH), as these indications may already qualify for Part D coverage. Patients must also meet specified obesity criteria, including a body mass index threshold.

CMS has also released implementation resources for prescribers and pharmacies to support the rollout. Beneficiaries interested in participating are encouraged to discuss treatment options with their physician and confirm their eligibility through CMS guidance.

Beyond providing near-term access to obesity medicines, the demonstration has an important evidence-generation role. CMS plans to collect data on GLP-1 utilization, adherence, and program costs and share these findings with Medicare Part D sponsors as it evaluates whether and how the BALANCE Model could eventually be implemented.

The demonstration has also created new questions about how it will interact with other Medicare drug pricing reforms. From January 1, 2027, negotiated prices under the Medicare Drug Price Negotiation Program will take effect for semaglutide products, including Wegovy. However, the price agreed under the Medicare GLP-1 Bridge is understood to be lower than the negotiated Medicare price, meaning CMS will need to clarify how the two pricing arrangements and their associated manufacturer obligations will operate alongside one another. The agency has indicated that further guidance will be issued.

The Medicare GLP-1 Bridge and BALANCE Model are consistent with an approach proposed by health policy researchers before either initiative was announced. A July 2025 white paper from the Institute for Clinical & Economic Review (ICER) suggested that a Center for Medicare and Medicaid Innovation demonstration could expand access to GLP-1 therapies while generating real-world evidence on their long-term clinical and economic impact. The authors also cautioned that demonstration-based coverage could create unintended access barriers and would not, on its own, address longer-term affordability concerns. How the evidence generated through the Bridge shapes future Medicare coverage decisions remains to be seen.